Skip to main content
Federal Court of Appeal· 2008

Mayne Pharma (Canada) Inc. v. Sanofi-Aventis Canada Inc.

2008 FCA 21
Intellectual PropertyJD
Cite or share
Share via WhatsAppEmail
Showing the official court-reporter headnote. An editorial brief (facts · issues · held · ratio · significance) is on the roadmap for this case. The judgment text below is the authoritative source.

Court headnote

Mayne Pharma (Canada) Inc. v. Sanofi-Aventis Canada Inc. Court (s) Database Federal Court of Appeal Decisions Date 2008-01-15 Neutral citation 2008 FCA 21 File numbers A-456-05 Notes Digest Decision Content Date: 20080115 Docket: A-456-05 Citation: 2008 FCA 21 CORAM: LÉTOURNEAU J.A. PELLETIER J.A. TRUDEL J.A. BETWEEN: MAYNE PHARMA (CANADA) INC. Appellant and AVENTIS PHARMA ET AL Respondents Heard at Ottawa, Ontario, on January 15, 2008. Judgment delivered from the Bench at Ottawa, Ontario, on January 15, 2008. REASONS FOR JUDGMENT OF THE COURT BY: PELLETIER J.A. Date: 20080115 Docket: A-456-05 Citation: 2008 FCA 21 CORAM: LÉTOURNEAU J.A. PELLETIER J.A. TRUDEL J.A. BETWEEN: MAYNE PHARMA (CANADA) INC. Appellant and AVENTIS PHARMA INC. and THE MINISTER OF HEALTH Respondents REASONS FOR JUDGMENT OF THE COURT (Delivered from the Bench at Ottawa, Ontario, on January 15, 2008) PELLETIER J.A. [1] At the commencement of the hearing of this appeal from an order of prohibition, we were advised that the patent which was the subject of the Notice of Allegation had been de-listed, that the de-listing had been upheld by the Federal Court and that the appeal period had expired without an appeal being taken from the decision of the Federal Court. [2] In light of this state of affairs, the appellant seeks to reinstate its motion for an order setting aside the order of prohibition on the ground that there is no longer a substrate for the order. The respondent contends that the basis for the pro…

Read full judgment
Mayne Pharma (Canada) Inc. v. Sanofi-Aventis Canada Inc.
Court (s) Database
Federal Court of Appeal Decisions
Date
2008-01-15
Neutral citation
2008 FCA 21
File numbers
A-456-05
Notes
Digest
Decision Content
Date: 20080115
Docket: A-456-05
Citation: 2008 FCA 21
CORAM: LÉTOURNEAU J.A.
PELLETIER J.A.
TRUDEL J.A.
BETWEEN:
MAYNE PHARMA (CANADA) INC.
Appellant
and
AVENTIS PHARMA ET AL
Respondents
Heard at Ottawa, Ontario, on January 15, 2008.
Judgment delivered from the Bench at Ottawa, Ontario, on January 15, 2008.
REASONS FOR JUDGMENT OF THE COURT BY: PELLETIER J.A.
Date: 20080115
Docket: A-456-05
Citation: 2008 FCA 21
CORAM: LÉTOURNEAU J.A.
PELLETIER J.A.
TRUDEL J.A.
BETWEEN:
MAYNE PHARMA (CANADA) INC.
Appellant
and
AVENTIS PHARMA INC. and
THE MINISTER OF HEALTH
Respondents
REASONS FOR JUDGMENT OF THE COURT
(Delivered from the Bench at Ottawa, Ontario, on January 15, 2008)
PELLETIER J.A.
[1] At the commencement of the hearing of this appeal from an order of prohibition, we were advised that the patent which was the subject of the Notice of Allegation had been de-listed, that the de-listing had been upheld by the Federal Court and that the appeal period had expired without an appeal being taken from the decision of the Federal Court.
[2] In light of this state of affairs, the appellant seeks to reinstate its motion for an order setting aside the order of prohibition on the ground that there is no longer a substrate for the order. The respondent contends that the basis for the prohibition order is the infringement of the patent which, notwithstanding the de-listing, remains valid and in force.
[3] We are of the view that we should intervene. The prohibition order is a remedy which is only available to a patent holder in the context of the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regs.). If the prohibition order is allowed to stand, the respondent will have the benefit of a remedy which is not available outside the context of the PM(NOC) Regs in a case where no basis exists under those regulations for the remedy.
[4] The respondent seeks to meet this argument by pointing out that the foundation of the order is the patent which, as noted, remains valid and in force. The respondent cannot invoke the PM(NOC) Regs in order to obtain a prohibition order and then argue the PM(NOC) Regs are irrelevant to that order. The respondent’s remedy is by way of an infringement action.
[5] While the matter was raise by motion, we are of the view that it goes to the merits of the appeal. Accordingly, for the reasons stated, the appeal will be allowed, the decision of the Federal Court granting the prohibition order will be set aside as of this date and the application for a prohibition order will be dismissed as of this date. The order for costs in the Federal Court will not be disturbed. The appellant is entitled to the costs of the appeal.
"J.D. Denis Pelletier"
J.A
FEDERAL COURT OF APPEAL
NAMES OF COUNSEL AND SOLICITORS OF RECORD
DOCKET: A-456-05
STYLE OF CAUSE: MAYNE PHARMA (CANADA) INC. and SANOFI-AVENTIS CANADA INC. and MINISTER OF HEALTH
PLACE OF HEARING: Ottawa, Ontario
DATE OF HEARING: January 15, 2008
REASONS FOR JUDGMENT OF THE COURT BY: LÉTOURNEAU J.A.
PELLETIER J.A.
TRUDEL J.A.
DELIVERED FROM THE BENCH BY: PELLETIER J.A.
APPEARANCES:
Susan Beaubien
FOR THE APPELLANT
Pascale-Catherine Guay
FOR THE RESPONDENT
SOLICITORS OF RECORD:
Macera & Jarzyna LLP
Ottawa, Ontario
FOR THE APPELLANT
John H. Sims Q.C
Deputy Attorney General of Canada
Ottawa, Ontario
FOR THE RESPONDENT

Source: decisions.fca-caf.gc.ca